产品
编 号：F106518
分子式：C18H25N5S2
分子量：375.55
分子式：C18H25N5S2
分子量：375.55
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1271738-59-0
产品详情
生物活性：
MI-3 (Menin-MLL inhibitor 3) is a potent and high affinity menin-MLL inhibitor with an IC50 of 648 nM and a Kd of 201 nM.
体外研究：
MI-3 (12.5-50 μM; HEK293 cells) treatment effectively inhibits the menin-MLL-AF9 interaction in human cells.MI-3 (0-1.6 μM; 72 hours; KOPN-8 and MV4;11 cells) treatment shows an effective and dose-dependent growth inhibition in KOPN-8, MV4 and ME-1 cells.MI-3 (12.5-50 μM; 48 hours; MV4;11 cells) treatment results in a substantial, and dose-dependent increase in Annexin V and AnnexinV/propidium iodide (PI) cells, demonstrating an increase in the number of cells undergoing apoptosis.MI-3 (6.25-25 μM; 6 days; THP-1 cells) treatment results in substantially reduced expression of HOXA9 and MEIS1.
MI-3 (Menin-MLL inhibitor 3) is a potent and high affinity menin-MLL inhibitor with an IC50 of 648 nM and a Kd of 201 nM.
体外研究：
MI-3 (12.5-50 μM; HEK293 cells) treatment effectively inhibits the menin-MLL-AF9 interaction in human cells.MI-3 (0-1.6 μM; 72 hours; KOPN-8 and MV4;11 cells) treatment shows an effective and dose-dependent growth inhibition in KOPN-8, MV4 and ME-1 cells.MI-3 (12.5-50 μM; 48 hours; MV4;11 cells) treatment results in a substantial, and dose-dependent increase in Annexin V and AnnexinV/propidium iodide (PI) cells, demonstrating an increase in the number of cells undergoing apoptosis.MI-3 (6.25-25 μM; 6 days; THP-1 cells) treatment results in substantially reduced expression of HOXA9 and MEIS1.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备